Corporate Partners
Boston Scientific Corporation
Boston Scientific Corporation (BSC) of Natick, MA, is a multibillion dollar firm traded on the NYSE and is the world's largest medical device company dedicated to less-invasive therapies. The Company's products are used in a broad range of interventional medical specialties, such as interventional cardiology, interventional radiology, peripheral vascular and neurovascular procedures, oncology, vascular surgery, endoscopy, urology and gynecology procedures.
BSC acquired worldwide exclusive rights from Angiotech to use paclitaxel in connection with its coronary stent products and has co-exclusive rights to certain other vascular and non-vascular products. BSC launched its TAXUS® stent in Europe and other international markets in February 2003 and in the United States in March 2004.
Genzyme Corporation
In May 2006, Angiotech entered into a strategic collaboration agreement with Genzyme Corporation to create novel, localized treatments for cancer patients that target the prevention of tumor re-growth after surgery through the direct application of a combined biomaterial / anti-cancer therapeutic at the site of tumor excision. These potential products may also be useful in treating inoperable tumors, reducing local tumor side-effects, and improving surgical outcomes while complementing existing systemic therapies. Under the collaboration agreement, the companies will conduct research jointly, with both companies contributing key personnel, technology and intellectual property.
Cook Incorporated
Privately-owned Cook Incorporated of Bloomington, Indiana is a leading provider of minimally invasive medical devices used worldwide by medical professionals in interventional radiology and cardiology, general surgery and critical care medicine. In 2004, Cook initiated the first U.S. clinical trial of a drug-eluting stent for a peripheral (non-coronary) artery. The DESTINY trial will investigate the use of the Zilver®PTX paclitaxel-eluting stent in the above-the-knee femoropopliteal artery. The company was also the first to conduct multi-center dose ranging studies (ASPECT and ELUTES) of paclitaxel-eluting coronary stents to treat restenosis. Its first drug-eluting medical device, the paclitaxel-eluting V-Flex™ Plus PTX Coronary Stent, received CE mark approval for sale in Europe based on Cook's strong clinical data from ELUTES and ASPECT. In 2004, Cook elected to exit the coronary vascular field of use and focus efforts on the peripheral vascular and gastrointestinal fields of use. Since its founding in 1963, COOK® has created innovative technologies for stents and stent-grafts, catheters, wire guides, introducer needles and sheaths, embolization coils, tissue-engineered medical biomaterials, vena cava filters, implanted cardiac lead extraction equipment and other minimally invasive medical devices.
Baxter Healthcare Corporation
Baxter Healthcare Corporation of Deerfield, Illinois, is a leader in the field of biosurgery with a well-established global sales force and is uniquely positioned to optimize the delivery of surgical products to the physicians and patients.
In February of 2003, Angiotech initiated a strategic alliance with Baxter, which consists of upfront payments and milestones, to provide them with worldwide (excluding Japan and certain other territories) rights to sell market, distribute and manufacture CoSeal® (surgical sealant product)and Adhibit™ (anti-adhesive product). In addition, Baxter will pay Angiotech royalties on sales of these products. In April 2003, we broadened the strategic alliance to provide Baxter with manufacturing rights for CoSeal and Adhibit. We have retained all development and commercial rights for drug-loaded versions of CoSeal and Adhibit.
Orthovita
Orthovita, Inc. is a specialty orthopedics company that develops and markets synthetic biomaterials for use in fracture repair and orthopedic trauma, spine surgery including spinal fusion, repair of osteoporosis-related fractures of the spine and other orthopedic applications. Orthovita's products represent fully synthetic alternatives to the use of autograft or cadaver-derived bone material in orthopedic and spine surgery.
In June 2004, Angiotech entered a North American sales and distribution agreement for its Vitagel™Surgical Hemostat with Orthovita. Angiotech also made a US$25 million equity investment in Orthovita. In October 2005, Angiotech agreed to transfer manufacturing rights for Vitagel to Orthovita and will receive royalties on future end-user sales of Vitagel by Orthovita. Angiotech has retained all development and commercial rights for drug-loaded versions of this product.